Fluoxetina ou Hypericum perforatum no tratamento de pacientes portadores de transtorno depressivo maior leve a moderado? Uma revisão
Conteúdo do artigo principal
Resumo
Detalhes do artigo
Referências
Kaplan HI, Sadock BJ. Tratado de psiquiatria. 6a ed. Porto Alegre: Artmed; 1999; p.1175.
Nicolau PFM. Classificação DSM-IV códigos e categorias dos eixos I e II. [cited 2011 June 14]. Available from: http://www.psiquiatriageral.com.br/dsm4/dsm_iv.htm
Stahl SM. Psicofarmacologia: base neurocientífica e aplicações práticas. 2a ed. Rio de Janeiro: MedSi; 2002:130-233.
Kulkarni SK, Dhir A. Effect of various classes of antidepressants in behavioral paradigms of despair. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1248-54. http://dx.doi.org/10.1016/j.pnpbp.2007.05.002
Gambarana C, Tolu PL, Masi F, Rinaldi M, Giachetti D, Morazzoni P, et al. A study of the antidepressant activity of Hypericum perforatum on animal models. Pharmacopsychiatry. 2001;34(Suppl 1):S42-4. http://dx.doi.org/10.1055/s-2001-15515
Linde K. St. John's Wort: an Overview. Forsch Komplementmed. 2009;16:146-55. http://dx.doi.org/10.1159/000209290
Preskorn SH. Comparision of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry. 1995;56(Suppl 6):12-21.
Miller AL. St. John's wort Hypericum perforatum: clinical effects on depression and other conditions. Alt Med Rev. 1998;3(1):18-26.
Schatzberg A, Nemeroff C. The american psychiatric publishing textbook of psychopharmacology. 3rd ed. Washington, USA: American Psychiatric Publishing. 2004;231.
Snow JM. Hypericum perforatum L. (Hyperiaceae). Protocol J Bot Med. 1996;2:16-21.
Müller WE, Kasper S. Clinically used antidepressant drugs. Pharmacopsychiatry. 1997;30(Suppl 2):71. http://dx.doi.org/10.1055/s-2007-979521
Mueller SC, Uehleke B, Woehling H, Petzsch M, Majcher-Peszynska J, Hehl EM, et al. Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin. Clin Pharmacol Ther. 2004;75(6): 546-57. http://dx.doi.org/10.1016/j.clpt.2004.01.014
Brattström A. Long-term effects of St.John'swort Hypericum perforatum treatment: A 1- year safety study in mild to moderate depression. Phytomedicine. 2009;16:277-283. http://dx.doi.org/10.1016/j.phymed.2008.12.023
Müller WEG, Rossol R. Effects of Hypericum extract on expression of serotonin receptors. J Geriatr Psychiatry Neurol. 1994;7:S63-S64. http://dx.doi.org/10.1177/089198879400700117
Müller WE, Rolli M, Schäfer, et al. Effects of Hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry. 1997;30(Suppl 2):S102-7. http://dx.doi.org/10.1055/s-2007-979528
Perovic S, Müller WE. Pharmacological profile of Hypericum extract. Arzneimittelforschung. 1995;45(11):1145-48.
Neary JT, Bu Y. Hypericum LI 160 inhibits uptake of serotonin and norepinephrine in astrocytes. Behav Brain Res. 1999;816(2):358-63. http://dx.doi.org/10.1016/S0006-8993(98)01126-3
Chatterjee SS, Bhattacharya SK, Wonnemann M, et al. Hyperforin as a possible antidepressant component of Hypericum extracts. Life Sci. 998;63(6):499-510.
Breidenbach T, Kliem V, Burg M, Radermacher J, Hoffmann MW, Klempnauer J. Profound drop of cyclosporin A whole blood trough levels caused by St. John's wort Hypericum perforatum. Transplantation. 2000;69(10): 2229-30. http://dx.doi.org/10.1097/00007890-200005270-00052
Teufel-Mayer R, Gleitz J. Effects of long-term administration of Hypericum extracts on the affinity and density of the central serotonergic 5-HT1 A and 5-HT2 A receptors Pharmacopsychiatry. 1997;(Suppl 2):113-6. http://dx.doi.org/10.1055/s-2007-979530
Nathan PJ. Hypericum perforatum St John's Wort: a non-selective reuptake inhibitor? A review of the recent advances in its pharmacology. J Phychopharm. 2001;15:(1)47-54. http://dx.doi.org/10.1177/026988110101500109
Kumar V, Singh PN, Muruganandam AV, Bhattacharya SK. Hypericum perforatum: nature's mood stabilizer. Indian J Exp Biol. 2000;38(11): 1077-85.
Tadros MG, Mohamed MR, Youssef AM, Sabry GM, Sabry NA, Khalifa AE. Involvement of serotoninergic 5-HT1A/2A, alpha-adrenergic and dopaminergic D1 receptors in St. John's Wort-induced prepulse inhibition deficit: a possible role of hyperforin. Beh Brain Res. 2008;199:334-9. http://dx.doi.org/10.1016/j.bbr.2008.12.015
Baureithel KH, Buter KB, Engesser A, et al. Inihibition of benzodiazepine binding in vitro by amentoflavone, a consituent of various species of Hypericum. Pharm Acta Helv. 1997;72(3):153-7. http://dx.doi.org/10.1016/S0031-6865(97)00002-2
Grundmann O, Lva Y, Kelber O, et al. Mechanism of St. John's wort extract STW3-VI) during chronic restraint stress is mediated by the interrelationship of the immune, oxidative defense, and neuroendocrine system. Neuropharmacology. 2010;58:767-73. http://dx.doi.org/10.1016/j.neuropharm.2009.12.014
Jungke P, Ostrow G, Li JL, Norton S, Nieber K, Kelber O, et al. Profiling of hypothalamic and hippocampal gene expression in chronically stressed rats treated with St. John's wort extract (STW 3-VI) and fluoxetine. Psychopharmacology. 2011;213:757-72. http://dx.doi.org/10.1007/s00213-010-2032-3
Bjerkenstedt L, Edman G, Alken R, et al. Hypericum extract LI 160 and fluoxetine in mild to moderate depression. Eur Arch Psychiatry Clin Neurosci 2005;255(1):40-7. http://dx.doi.org/10.1007/s00406-004-0532-z
Moreno RA, Teng CT, Almeida KM, et al. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression: a randomized double-blind trial in a Brazilian sample.Rev Bras Psiquiatr. 2006;28(1):29-32. http://dx.doi.org/10.1590/S1516-44462006000100007
PapakostaGI, Crawford CM, Scalia MJ, et al. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder a replication of findings with the use of a double-blind, placebo-controlled trial of Hypericum perforatum versus fluoxetine. Neuropsych. 2007;(56): 132-37.
Murck H, Fava M, Alpert J, Nierenberg AA, Mischoulon D, Otto MW, et al. Hypericum extract in patients with MDD and reversed vegetative signs: re-analysis from data of a double-blind, randomized trial of Hypericum extract, fluoxetine, and placebo. Int J Neuropsychofarmacol. 2005;(8): 215-21.
Fava M, Alpert J, Nierenberg AA, Mischoulon D, Otto MW, Zajecka J, et al. A double-blind, randmized trial of St. John's wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol. 2005;25(5):441-7. http://dx.doi.org/10.1097/01.jcp.0000178416.60426.29
Hypericum Depression Trial Study roup. Effect of Hypericum perforatum of St John's wort in major depressive disorder: a randomized controlled trial. JAMA. 2002;287(14):1807-14. http://dx.doi.org/10.1001/jama.287.14.1807
Shelton RC, Keller MB, Gelenberg A, Dunner DL, Hirschfeld R, Thase ME, et al. Effectiveness of St John's wort in major depression: a randomized controlled trial. JAMA. 2001;18;285(15):1978-86.
Cipriani A, Brambilla P, Furukawa TA, Geddes J, Gregis M, Hotopf M, et al. Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database of Systematic Reviews. Issue 06; 2011.